Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

129
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
129
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Standards of Care II01:19

Standards of Care II

905
Nurses bear specific legal responsibilities under several federal statutes, including:
905

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

British journal of haematology·2026
Same author

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed <i>FLT3</i>-ITD-negative acute myeloid leukemia.

Future oncology (London, England)·2026
Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026
Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

The New England journal of medicine·2026
Same author

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026

Related Experiment Video

Updated: Nov 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

452

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.

Daniel A Pollyea1, Dale Bixby2, Alexander Perl3

  • 11University of Colorado Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|January 6, 2021
PubMed
Summary

The NCCN Guidelines for Acute Myeloid Leukemia (AML) offer updated treatment recommendations. Key updates include genetic alterations, specific leukemia subtypes, venetoclax use, and transfusion alternatives.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.0K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.5K

Related Experiment Videos

Last Updated: Nov 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

452
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.0K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.5K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Guidelines

Background:

  • The National Comprehensive Cancer Network (NCCN) Guidelines provide evidence-based recommendations for cancer treatment.
  • Acute Myeloid Leukemia (AML) is a complex hematologic malignancy requiring tailored treatment strategies.
  • Recent clinical trials and research have introduced new insights into AML management.

Purpose of the Study:

  • To summarize recent updates to the NCCN Guidelines for Acute Myeloid Leukemia (AML).
  • To highlight advancements in diagnosis and treatment strategies for adult AML patients.
  • To provide physicians with current information for clinical decision-making in AML.

Main Methods:

  • Review of recent clinical trials and scientific literature relevant to AML.
  • Analysis of new data on prognostic factors and treatment efficacy.
  • Integration of updated information into the NCCN Clinical Practice Guidelines for AML.

Main Results:

  • Updates address familial genetic alterations in AML.
  • Revised recommendations for postinduction/postremission strategies in low-risk acute promyelocytic leukemia and favorable-risk AML.
  • New principles for venetoclax-based therapies and transfusion alternatives are included.

Conclusions:

  • The NCCN Guidelines provide crucial updates for managing adult AML.
  • These insights support personalized treatment approaches based on genetic factors and patient preferences.
  • Adherence to updated guidelines can improve outcomes for AML patients.